MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too

A ruling from the U.S. Patent and Trademark Office pushes Novartis’ exclusivity on Gilenya from 2019 to 2027. That will give Celgene more time to secure FDA approval for its Gilenya rival and pe…
Read the full story: FiercePharma: Pharma